Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
MONDAY, APRIL 27, 2026
08:30 - 09:30
REGISTRATION AND MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
LATEST ADVANCEMENTS IN MRNA FORMULATION AND DELIVERY TECHNOLOGIES
Pintu Kanjilal
Strand Therapeutics

Pintu Kanjilal

Strand Therapeutics

  • Emphasizing the need for robust delivery platforms enabling clinical mRNA therapies
  • Enumerating delivery strategies applied to achieve efficient, reliable mRNA transport
  • Affirming LNPs as preferred vehicles for mRNA drug products in development and commercialization
  • Summarizing key learnings from recent LNP programs spanning formulation and safety
10:05 - 10:10
Q&A SESSION ON ADVANCES IN MRNA FORMULATION AND DELIVERY
10:10 - 10:40
SPEED NETWORKING SESSION
  • Exchange business cards and get connected in short one-to-one meetings
  • Start the conversation to arrange a more formal meeting later on in the conference
  • Share your professional background and discuss your biggest business issues – don't forget your business cards!
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON MRNA
11:30 - 11:55
MECHANISMS OF ENDOSOMAL ESCAPE AND INTRACELLULAR DELIVERY MEDIATED BY LIPID NANOPARTICLE COMPONENTS
Ismail Hafez
Ionis Pharmaceuticals Inc.

Ismail Hafez

Ionis Pharmaceuticals Inc.

  • Establishing how lipid nanoparticles enable intracellular delivery of mRNA via endosomal pathways
  • Differentiating the roles of ionizable, helper, and sterol lipids in endosomal rupture and mRNA release
  • Evaluating revised models of ionizable lipid-mediated endosomal escape against current evidence
11:55 - 12:00
Q&A SESSION ON LNP ENDOSOMAL ESCAPE AND DELIVERY MECHANISMS
12:00 - 12:25
MODULAR MICRO-FACTORIES FOR AGILE AND SCALABLE MRNA PRODUCTION
Andreas Traube
Fraunhofer IPA

Andreas Traube

Fraunhofer IPA

  • Modularizing flexible production units to enable efficient, parallelized mRNA manufacturing
  • Monitoring quality continuously while automation reduces batch variability and speeds scale-out
  • Extending modular micro-factories from decentralized sites to rapid response personalized platforms
12:25 - 12:30
Q&A SESSION ON MODULAR MICRO-FACTORIES
12:30 - 13:30
NETWORKING LUNCH & VISITING THE MRNA EXHIBITION
13:30 - 13:55
TAILORED AND STABLE NON-PEG FOR MRNA VACCINES
George Dakwar
CureVac

George Dakwar

CureVac

  • Ensuring thermo-stable, safe, and effective mRNA vaccines for infectious disease use
  • Proposing a proprietary non-PEG alternative with advantages and a feasible path forward
  • Advancing optimized LNP designs for oncology applications with stability and delivery gains
13:55 - 14:00
Q&A SESSION ON NON-PEG APPROACHES FOR MRNA VACCINES
14:00 - 14:25
HIXCAP™: CAP ANALOGS RATIONALLY DESIGNED FOR IMMUNE EVASION AND TRANSLATIONAL EFFICIENCY IN MRNA THERAPEUTICS
David Butler
Hongene Biotech Corporation

David Butler

Hongene Biotech Corporation

  • Structuring novel 5′ cap analogs to improve translation in immunologically active environments
  • Counteracting IFIT1-mediated suppression to enhance mRNA output under inflammatory conditions
  • Positioning HiXCap™ E2 for trials after efficacy in JAWS II cells, LPS mice, and case studies
14:25 - 14:30
Q&A SESSION ON 5' CAP ANALOGS FOR MRNA TRANSLATION
14:30 - 14:55
PROBLEMS WITH LONG MRNA SYNTHESIS? – CONGESTION ON THE DNA TEMPLATE GENERATES RNA FRAGMENTS VIA POLYMERASE BUMPING
Craig Martin
University of Massachusetts

Craig Martin

University of Massachusetts

  • Investigating polymerase bumping on crowded DNA templates that generate truncated RNA
  • Quantifying how polymerase density on DNA governs collision frequency and fragment yield
  • Preventing bumping through co-tethered transcription to restore full-length mRNA output
14:55 - 15:00
Q&A SESSION ON POLYMERASE BUMPING IN MRNA SYNTHESIS
15:00 - 15:30
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:30 - 15:55
GENERATIVE DESIGN OF COMPLETE THERAPEUTIC MRNA MOLECULES
Aidan Riley
Gardn Biosciences

Aidan Riley

Gardn Biosciences

  • Integrating 5′ UTR, coding sequence, and 3′ UTR in one pass to optimize full-length mRNA
  • Showing optimized linear mRNA constructs outperform circular RNA in expression and in vivo utility
  • Achieving cell type specificity, lower immunogenicity, and manufacturability via end-to-end design
15:55 - 16:00
Q&A SESSION ON GENERATIVE DESIGN OF THERAPEUTIC MRNA
16:00 - 16:25
RNA THERAPEUTICS: MULTI-MODALITY POTENTIAL FROM GENE SILENCING THROUGH THERAPEUTICS
Anis H Khimani
ZeptoMetrix Corporation

Anis H Khimani

ZeptoMetrix Corporation

  • Tracing the shift from transcriptional paradigms to therapeutic applications with context
  • Surveying a broad pipeline spanning therapeutic areas and modalities across RNA medicines
  • Anticipating challenges and future opportunities for multi modal RNA therapeutics
16:25 - 16:30
Q&A SESSION ON MULTI-MODAL RNA THERAPEUTICS
16:30 - 17:00
RESERVED PRESENTATION
17:00 - 18:00
NETWORKING DRINKS RECEPTION
Day 2 :
TUESDAY, APRIL 28, 2026
09:00 - 09:30
MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
ENGINEERED EXTRACELLULAR VESICLES ENGINEERED WITH MRNA FOR TREATMENT OF DEGENERATIVE DISC DISEASE
Wenchun Qu
Mayo Clinic

Wenchun Qu

Mayo Clinic

  • Highlighting potent immunomodulatory effects of mRNA-engineered extracellular vesicles
  • Addressing disc regeneration using mRNA-based therapeutics to restore structure and function
  • Contextualizing EV design and delivery variables that influence targeting to disc tissues
10:05 - 10:10
Q&A SESSION ON ENGINEERED EV FOR MRNA THERAPEUTICS
10:10 - 10:35
ENGINEERING MRNA FOR SUCCESS: BAYESIAN NETWORKS FOR MAXIMUM EXPRESSION AND TISSUE SPECIFICITY
Davide De Lucrezia
TriLink BioTechnologies

Davide De Lucrezia

TriLink BioTechnologies

  • Harnessing graph theory and Bayesian networks to improve in vivo expression and tissue specificity
  • Designing sequence constructs, capping analogs, and modifications with data-driven prioritization
  • Streamlining construct generation and evaluation through the intuitive Mercurius Builder workflow
10:35 - 10:40
Q&A SESSION ON BAYESIAN NETWORKS FOR mRNA EXPRESSION
10:40 - 11:05
ANTISENSE BASED MICROBIAL TARGETING VIA ANTIBODY-NANOPARTICLE CONJUGATES
Brandon Armstead
Brown University Health

Brandon Armstead

Brown University Health

  • Formulating antibody-targeted nanoparticles to deliver antisense oligos to septic pathogens
  • Profiling pathogen gene targets from whole-blood diagnostics to guide selective depletion plans
  • Conjugating surface antibodies to improve targeting and delivery of gene-silencing cargo
11:05 - 11:10
Q&A SESSION ON ANTISENSE NANOPARTICLE SEPSIS TARGETING
11:10 - 11:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:30 - 11:55
REVSELECT™ AI-POWERED 5′ UTR OPTIMIZATION DRIVING 65% HIGHER PROTEIN EXPRESSION AND ACCELERATED PATHWAYS FOR PERSONALIZED MRNA THERAPEUTICS
Molly McGlaughlin
Revolution Biomanufacturing Inc.

Molly McGlaughlin

Revolution Biomanufacturing Inc.

  • Optimizing 5′ and 3′ UTRs with AI models to refine ribosome loading and translation outcomes
  • Leveraging pretrained language models and structural features to predict translational efficiency
  • Demonstrating 65% gains in protein expression using validated UTR designs across models
  • Identifying novel IRES elements with improved precision to advance personalized mRNA use
11:55 - 12:00
Q&A SESSION ON AI-POWERED UTR OPTIMIZATION FOR MRNA
12:00 - 12:25
UNLOCKING RNA THERAPEUTICS IN CANCER AND AUTOIMMUNE DISEASE USING A REDOSABLE PEPTIDE-BASED NANOPARTICLE PLATFORM
Gilles Divita
Aanastra

Gilles Divita

Aanastra

  • Developing AI-driven peptide nanoparticles to enable targeted RNA delivery at scale
  • Expanding extrahepatic reach with PEP-NP™ peptide nanoparticles for selective mRNA delivery
  • Realizing in vivo mRNA-based CAR-T engineering using targeted peptide nanoparticles
12:25 - 12:30
Q&A SESSION ON REDOSABLE PEPTIDE NANOPARTICLE FOR MRNA DELIVERY
12:30 - 12:55
IMPURITY CHARACTERIZATION AND CONTROL DURING MRNA PRODUCTION
Kok-Seong Lim
Independent Consultant

Kok-Seong Lim

Independent Consultant

  • Pinpointing key impurity sources in mRNA production, including dsRNA and mRNA–lipid adducts
  • Implementing analytical methods for accurate detection and quantification of impurities
  • Reducing impurities via practical steps, in-process controls, and post-purification optimization
12:55 - 13:00
Q&A SESSION ON IMPURITY CONTROL IN mRNA PRODUCTION
13:00 - 13:15
FEEDBACK & RAFFLE DRAW
13:15 - 14:30
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.